Sandoz growth strategy in Japanese market - From Global Generics - PowerPoint PPT Presentation

Sandoz growth strategy in Japanese market - From Global Generics company perspective - Junichi Nakamichi, Country Head, Sandoz K.K. IGPA Kyoto December 2012 a Novartis company

Agenda Sandoz overview Leadership in differentiated generics Sandoz strategy for Japan 2 | Sandoz Growth Strategy in Japanese Market | J. Nakamichi | IGPA Kyoto 2012

Sandoz is a Novartis Group Company 2011 sales USD billion Environment Patient needs Novartis portfolio Innovative Pharmaceuticals 32.5 medicines Eye Care 10.0 (Alcon, CIBA VISION) Full range Affordable Sandoz – Generics 9.5 of options healthcare options Consumer Health Self-care 4.6 (OTC, Animal Health) Vaccines and Prevention 2.0 Diagnostics 3 | Sandoz Growth Strategy in Japanese Market | J. Nakamichi | IGPA Kyoto 2012

Novartis’ mission is to care for and cure patients In 2011, Novartis treated and protected more than 1 billion patients around the world with our products and Sandoz medicines reached over 400 million patients 4 | Sandoz Growth Strategy in Japanese Market | J. Nakamichi | IGPA Kyoto 2012

Sandoz sales grew at double-digit since 2009 Sandoz third-party sales USD billion 9.5 +12% CAGR 8.6 7.5 2009 2010 2011 5 | Sandoz Growth Strategy in Japanese Market | J. Nakamichi | IGPA Kyoto 2012

Sandoz roots in high-quality medicines run deep 2009 1992 2010 1986 Sabex 2011 Durascan Amifarma 2012 1946 Apothecon, Lagap, Aventis cephalosporins BASF Generics, Grandis, Labinca Wyeth penicillins, Invamed, SBPA Hoechst fermentation 1946 Azupharma Biochemie Roferm 1886 Geneva Servipharm Rolab 1859 CIBA 2003 1758 Multipharma Geigy 1940 1960 1980 2000 2010 6 | Sandoz Growth Strategy in Japanese Market | J. Nakamichi | IGPA Kyoto 2012

Sandoz operates in 140 countries globally Development* Subsidiaries Unterach Holzkirchen Barleben Rudolstadt Production* Representative offices Strykow Boucherville Kundl / Schaftenau Ljubljana / Wilson Mengeš Broomfield Kaminoyama Candelaria Zhongshan Cambe/ Taboao Gebze Spartan Turbhe Kalwe Jakarta * Sample Sandoz manufacturing and development sites. 7 | Sandoz Growth Strategy in Japanese Market | J. Nakamichi | IGPA Kyoto 2012

Agenda Sandoz overview Leadership in differentiated generics Sandoz strategy for Japan 8 | Sandoz Growth Strategy in Japanese Market | J. Nakamichi | IGPA Kyoto 2012

Sandoz has an industry-leading breadth of technologies Biosimilars Lyophilization Ophthalmics Patches/ transdermals/ Hormones Injectables thin films Inhalers Cytotoxics API Innovative solid Implants Dermatology formulations 9 | Sandoz Growth Strategy in Japanese Market | J. Nakamichi | IGPA Kyoto 2012

Sandoz is the global pioneer in safe, effective biosimilars somatropin G-CSF • First biosimilar in EU; • Feb. 2009 EU approval approved May 2006 • Growing rapidly across • Broad global launch (e.g., EU markets US, Japan & LATAM) 2006 2007 2008 2009 2010 erythropoietin • Introduced for nephrology in Oct. 2007 • First EPO biosimilar in EU • Launched in Oncology (2009 & 2010) 10 | Sandoz Growth Strategy in Japanese Market | J. Nakamichi | IGPA Kyoto 2012

Sandoz is the world leader in developing, manufacturing and commercializing biosimilars Development expertise:  Pioneer – developing biosimilars since 1996  8-10 molecules in development, including mAbs Manufacturing experience:  Producing recombinant proteins since 1980  Full range of capabilities Commercial experience:  Broad global presence (marketing in ~50 countries) 11 | Sandoz Growth Strategy in Japanese Market | J. Nakamichi | IGPA Kyoto 2012

Agenda Sandoz overview Leadership in differentiated generics Sandoz strategy for Japan 12 | Sandoz Growth Strategy in Japanese Market | J. Nakamichi | IGPA Kyoto 2012

Sandoz Japan provides “Added - value” and “Trust through Reliability” by leveraging global assets Differentiation Addressing customer needs  Value-added products Difficult-to-make •  Onco-safe Biosimilars  • Globally integrated Pre-mixed / drug safety liquid vials management system  API  FDF* products  Japan experts  Quality standards  Diversified multi- culture  Talent People synergies Pursuing economies of scale *Finished dosage forms 13 | Sandoz Growth Strategy in Japanese Market | J. Nakamichi | IGPA Kyoto 2012

Business model deploying global scale merit - Concept For registration Local requirements Development Production FDF API sourcing Packaging Inspection / Marketing API QA Sales PMS FDF* Global Sharing Support Partial Support reports Japan *Finished dosage forms 14 | Sandoz Growth Strategy in Japanese Market | J. Nakamichi | IGPA Kyoto 2012

Sandoz mission “We will be the main provider of high quality, affordable medicines helping secure long-term access to healthcare for people around the world.” 15 | Sandoz Growth Strategy in Japanese Market | J. Nakamichi | IGPA Kyoto 2012